PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization

B Zafrir, A Egbaria, N Stein, A Elis, W Saliba - Journal of Clinical Lipidology, 2021 - Elsevier
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …
被引用次数：23 相关文章

PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization.

B Zafrir, A Egbaria, N Stein, A Elis… - Journal of Clinical …, 2020 - europepmc.org
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …

PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization

B Zafrir, A Egbaria, N Stein, A Elis… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …

PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization

B Zafrir, A Egbaria, N Stein, A Elis… - Journal of Clinical …, 2021 - lipidjournal.com
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …